- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07342608
Seguridad y Rendimiento del Electrodo de Marcapasos Cardiaco LINEA Optimizado para la Implantación en el Tabique Interventricular (STARLIGHT)
Seguridad y Rendimientos del Electrodo de Estimulación Cardíaca LINEA Optimizado para la Implantación en el Tabique Interventricular
The purpose of the clinical investigation is to evaluate the safety and performances of the new LINEA cardiac pacing lead, intended for placement at the interventricular septum.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Antoine Guihard
- Número de teléfono: +33 1 46 01 33 20
- Correo electrónico: antoine.guihard@cf.microport.com
Ubicaciones de estudio
-
-
-
Ghent, Bélgica
- Reclutamiento
- Ghent University Hospital
-
Contacto:
- Jan De Pooter
- Correo electrónico: jadpoote.depooter@ugent.be
-
-
-
-
-
Girona, España
- Reclutamiento
- Hospital Universitari de Girona Doctor Josep Trueta
-
Contacto:
- María Emilce Trucco
- Correo electrónico: metrucco.girona.ics@gencat.cat
-
Granada, España
- Reclutamiento
- Hospital Universitario Virgen de las Nieves
-
Contacto:
- Manuel Molina
- Correo electrónico: manuel.molina.lerma@gmail.com
-
Valencia, España
- Reclutamiento
- Hospital Universitari i Politècnic La Fe
-
Contacto:
- Óscar Cano
- Correo electrónico: oscape13@hotmail.com
-
-
-
-
-
Annecy, Francia
- Reclutamiento
- Centre Hospitalier Annecy Genevois
-
Contacto:
- Pierre Frey
- Correo electrónico: pfrey@ch-annecygenevois.fr
-
Clermont-Ferrand, Francia
- Reclutamiento
- CHU Clermont-Ferrand
-
Contacto:
- Pierre-Antoine Catalan
- Correo electrónico: pacatalan@chu-clermontferrand.fr
-
Grenoble, Francia
- Reclutamiento
- CHU Grenoble
-
Contacto:
- Adrien Carabelli
- Correo electrónico: acarabelli@chu-grenoble.fr
-
Montpellier, Francia
- Reclutamiento
- Clinique du Millénaire
-
Contacto:
- Nicolas Clémenty
- Correo electrónico: nicolas.clementy@gmail.com
-
Rouen, Francia
- Reclutamiento
- CHU Rouen Hôpital Charles Nicolle
-
Contacto:
- Raphaël Al Hamoud
- Correo electrónico: raphael.al-hamoud@chu-rouen.fr
-
Tours, Francia
- Reclutamiento
- Hôpital Trousseau
-
Contacto:
- Arnaud Bisson
- Correo electrónico: a.bisson@chu-tours.fr
-
-
-
-
-
Novara, Italia
- Reclutamiento
- Ospedale Maggiore della Carità - AO Univ.
-
Contacto:
- Gabriele Dell'Era
- Correo electrónico: gabriele.dellera@maggioreosp.novara.it
-
Pisa, Italia
- Reclutamiento
- Ospedale San Cataldo CNR - Fond. Toscana G. Monasterio
-
Contacto:
- Gianluca Mirizzi
- Correo electrónico: gmirizzi@ftgm.it
-
-
-
-
-
Coimbra, Portugal
- Reclutamiento
- ULS de Coimbra
-
Contacto:
- João Ferreira
- Correo electrónico: joaoaferreira29@gmail.com
-
Lisbon, Portugal
- Reclutamiento
- ULS Santa Maria
-
Contacto:
- Nelson Cunha
- Correo electrónico: nelsoncunha@campus.ul.pt
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria (phase I and II):
- Patient indicated for cardiac pacing according to the most recent guidelines from the European Society of Cardiology (ESC)
- Patient planned for a de novo implantation of an ALIZEA, BOREA or CELEA Single Chamber (SR) or Dual Chamber (DR) pacemaker from MicroPort CRM
- Patient planned for a catheter-guided ventricular pacing lead implantation in the interventricular septum area
- Patient's pacemaker with the remote monitoring functions accepted by the patient and planned to be activated
Exclusion criteria (phase I and II):
- Patient planned for a device upgrade, or a device or a lead replacement
- Patient with a congenital heart disease, hypertrophic cardiomyopathy or infiltrative cardiomyopathy
- Patient with a Left Ventricular Ejection Fraction (LVEF) ≤ 35%
- Patient already enrolled in another clinical investigation that could confound the results of this clinical investigation (e.g., clinical investigations involving intra-cardiac device)
- Patient having a contraindication for cardiac pacing system implantation (i.e. patient implanted with a defibrillator, patient for whom a single dose of steroid eluted by the pacing lead (e.g., dexamethasone sodium phosphate) is contraindicated, patient implanted with a tricuspid replacement heart valve, with prior tricuspid valve intervention or with a significant tricuspid valve disease that may lead to future replacement heart valve surgery)
- Patient with a life expectancy of less than 2 years
- Minor age patient (i.e. under 18 years of age)
- Incapacitated patient, under guardianship, kept in detention, refusing to cooperate or not able to understand the purpose of this clinical investigation
- Non-menopausal women
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Electrodo de estimulación cardíaca LINEA
|
Use of LINEA cardiac pacing lead and delivery catheter for implantation of pacemaker |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
LINEA lead complication free rate at 3 months
Periodo de tiempo: 3 months after implantation
|
Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
3 months after implantation
|
|
LINEA lead pacing threshold amplitude at 3 months
Periodo de tiempo: 3 months after implantation
|
Mean ventricular pacing threshold amplitude |
3 months after implantation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Success rate of LINEA lead minimum sensed amplitude
Periodo de tiempo: 3 months after implantation
|
Proportion of patients with minimum sensed amplitude ≥ 5 mV |
3 months after implantation
|
|
General performances of LINEA lead
Periodo de tiempo: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
Pacing threshold amplitude, impedance and minimum sensed amplitude obtained with the LINEA lead at each patient's visit. LBB pacing threshold amplitude obtained with the LINEA lead during implantation, as well as the chronaxie measurement |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the LINEA lead
Periodo de tiempo: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
LINEA lead complication free rate over time, calculated based on number of Adverse Events and Device Deficiencies related to the lead |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
Safety of the FLEXIGO delivery catheter and the FLEXIGO slitter
Periodo de tiempo: Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
FLEXIGO catheter complication free rate, calculated based on number of Adverse Events and Device Deficiencies related to the catheter or the slitter |
Implantation, 72 hours from implantation, 1 month, 3 months, 6 months, 18 months, 30 months and 42 months after implantation
|
|
LINEA lead implantation success rates
Periodo de tiempo: Implantation
|
Proportion of LINEA leads implanted in the interventricular septum and meeting or not LBBAP criteria |
Implantation
|
|
Lead and delivery catheter implantation time
Periodo de tiempo: Implantation
|
Total procedural time and total fluoroscopic time of each implantation |
Implantation
|
|
LINEA lead and FLEXIGO delivery catheter and slitter implantation usability
Periodo de tiempo: Implantation
|
Handling scores based on a specific questionnaire (scale Very poor/Poor/Acceptable/Good/Very good) |
Implantation
|
|
Right Ventricular Autothreshold performances
Periodo de tiempo: 3 months after implantation
|
- Accuracy - Comparison between the manual ventricular pacing threshold performed by a physician and the in-clinic ventricular pacing threshold provided by the RVAT function at the same pulse width and during the same on-site patient's visit |
3 months after implantation
|
|
Evolution of LBBAP capture over time
Periodo de tiempo: 18 months after implantation
|
- LBBAP capture evolution with analyses of ECGs (i.e. V6 R-wave peak time and V6-V1 interpeak interval) and LBBAP criteria collected |
18 months after implantation
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Early outcome - Absence of Unanticipated Serious Adverse Device Effect (USADE) related to LINEA lead
Periodo de tiempo: 1 month after implantation
|
Proportion of patients free from USADE. Any event caused by use of the LINEA lead or any accessory packaged with the lead, will be considered as an ADE related to the LINEA lead. The endpoint evaluation will be based on an independent safety events adjudication from a Clinical Events Committee (CEC), based on investigational site reporting |
1 month after implantation
|
|
Early outcome - LINEA lead pacing threshold amplitude at 1 month
Periodo de tiempo: 1 month after implantation
|
Mean ventricular pacing threshold amplitude |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Periodo de tiempo: 1 month after implantation
|
- Implantation success rate - Proportion of LINEA lead successfully implanted at the interventricular septum and fulfilling or not LBBAP success criteria according to the operator's decision |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Periodo de tiempo: 1 month after implantation
|
- Short term electrical performances variation - Pacing threshold variation between implantation and 1 month, and electrical performances of the LINEA lead (pacing threshold, impedance and minimum sensed amplitude) |
1 month after implantation
|
|
Early outcome - Other LINEA lead and FLEXIGO delivery catheter safety and performance
Periodo de tiempo: 1 month after implantation
|
- Complication free rate - Proportion of patients free from complication related to the LINEA lead. A complication is defined as a SADE with a probable or causal relationship to the LINEA lead which triggered an additional invasive intervention or resulted in patient death |
1 month after implantation
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- LLAI01 - STARLIGHT
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .